{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:38:39Z","timestamp":1792787919058,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"DOI":"10.1007\/s40268-026-00549-6","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:51:54Z","timestamp":1792727514000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population Pharmacokinetics of Intravenous and Subcutaneous Belimumab, and Clinical Response Prediction in Chinese Pediatric Patients with Systemic Lupus Erythematosus"],"prefix":"10.1007","author":[{"given":"Junyi","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Dimelow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5750-1728","authenticated-orcid":false,"given":"Xuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"issue":"11","key":"549_CR1","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1002\/art.11299","volume":"48","author":"KP Baker","year":"2003","unstructured":"Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003;48(11):3253\u201365.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"549_CR2","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1002\/art.23678","volume":"58","author":"M Petri","year":"2008","unstructured":"Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008;58(8):2453\u20139.","journal-title":"Arthritis Rheum"},{"key":"549_CR3","unstructured":"EMA. Benlysta: summary of product characteristics. 2024. Available from: www.ema.europa.eu\/en\/documents\/product-information\/benlysta-epar-product-information_en.pdf. Accessed 8 Aug 2024."},{"key":"549_CR4","unstructured":"GSK. GSK receives approval for Benlysta in Japan for the treatment of systemic lupus erythematosus. 2017. Available from: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-receives-approval-for-benlysta-in-japan-for-the-treatment-of-systemic-lupus-erythematosus\/. Accessed 1 Aug 2024."},{"key":"549_CR5","unstructured":"GSK. Benlysta prescribing information 2022. Available from: https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Benlysta\/pdf\/BENLYSTA-PI-MG-IFU.PDF. Accessed 1 Aug 2024."},{"key":"549_CR6","unstructured":"GSK. China\u2019s National Medical Products Administration approves Benlysta (belimumab) for adult patients with active lupus nephritis 2022. Available from: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/china-s-national-medical-products-administration-approves-benlysta-belimumab-for-adult-patients-with-active-lupus-nephritis\/. Accessed 8  Aug 2024."},{"issue":"4","key":"549_CR7","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s40268-021-00363-2","volume":"21","author":"X Zhou","year":"2021","unstructured":"Zhou X, Lee TI, Zhu M, Ma P. Prediction of belimumab pharmacokinetics in Chinese pediatric patients with systemic lupus erythematosus. Drugs R D. 2021;21(4):407\u201317.","journal-title":"Drugs R D"},{"key":"549_CR8","unstructured":"US FDA. NDA\/BLA multi-disciplinary review and evaluation BLA 761043\/s-027 and BLA 125370\/s-081. Belimumab. 2024. Available from: https:\/\/www.fda.gov\/media\/182222\/download. Accessed 17 May 2024."},{"issue":"7","key":"549_CR9","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/jcph.104","volume":"53","author":"H Struemper","year":"2013","unstructured":"Struemper H, Chen C, Cai W. Population pharmacokinetics of belimumab following intravenous administration in patients with systemic lupus erythematosus. J Clin Pharmacol. 2013;53(7):711\u201320.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"549_CR10","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s40262-017-0586-5","volume":"57","author":"H Struemper","year":"2018","unstructured":"Struemper H, Thapar M, Roth D. Population pharmacokinetic and pharmacodynamic analysis of belimumab administered subcutaneously in healthy volunteers and patients with systemic lupus erythematosus. Clin Pharmacokinet. 2018;57(6):717\u201328.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"549_CR11","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/bcp.16263","volume":"91","author":"J Wu","year":"2025","unstructured":"Wu J, Zhou X, Dimelow R, Marshall S. Inter-regional pharmacokinetics and exposure-response analyses of belimumab in patients with system lupus erythematosus. Br J Clin Pharmacol. 2025;91(2):374\u201385.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"549_CR12","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/acr.25700","volume":"78","author":"HI Brunner","year":"2026","unstructured":"Brunner HI, Ant\u00f3n J, Calvo-Penad\u00e9s I, et al. Pharmacokinetics, pharmacodynamics, and safety of subcutaneous belimumab in pediatric patients with systemic lupus erythematosus: a multicenter, open-label trial. Arthritis Care Res (Hoboken). 2026;78(6):761\u201370.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"549_CR13","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2020-217101","volume":"79","author":"HI Brunner","year":"2020","unstructured":"Brunner HI, Abud-Mendoza C, Viola DO, et al. Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann Rheum Dis. 2020;79(10):1340\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"549_CR14","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918\u201330.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"549_CR15","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","volume":"383","author":"R Furie","year":"2020","unstructured":"Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383(12):1117\u201328.","journal-title":"N Engl J Med"},{"issue":"9767","key":"549_CR16","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra SV, Guzm\u00e1n RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721\u201331.","journal-title":"Lancet"},{"issue":"5","key":"549_CR17","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/art.40049","volume":"69","author":"W Stohl","year":"2017","unstructured":"Stohl W, Schwarting A, Okada M, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. 2017;69(5):1016\u201327.","journal-title":"Arthritis Rheumatol"},{"key":"549_CR18","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1016\/j.ard.2025.06.1928","volume":"84","author":"C Li","year":"2025","unstructured":"Li C, Zhang J, Yu H, et al. A phase 4, multicentre, open-label study of intravenous belimumab in paediatric patients with active systemic lupus erythematosus in China. Ann Rheum Dis. 2025;84:2261\u20132.","journal-title":"Ann Rheum Dis"},{"key":"549_CR19","unstructured":"ClinicalTrials.gov. A study of belimumab in Chinese pediatric participants with systemic lupus erythematosus. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05917288?cond=belimumab%20&term=SC%20Pediatric%20China&rank=1. Accessed 8 Jan 2025."},{"issue":"4","key":"549_CR20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/psp4.12611","volume":"10","author":"DJ Irby","year":"2021","unstructured":"Irby DJ, Ibrahim ME, Dauki AM, et al. Approaches to handling missing or \u201cproblematic\u201d pharmacology data: pharmacokinetics. CPT Pharmacomet Syst Pharmacol. 2021;10(4):291\u2013308.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"1","key":"549_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/psp4.12052","volume":"5","author":"W Wang","year":"2016","unstructured":"Wang W, Hallow KM, James DA. A tutorial on RxODE: simulating differential equation pharmacometric models in R. CPT Pharmacomet Syst Pharmacol. 2016;5(1):3\u201310.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"3","key":"549_CR22","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/ard-2022-223035","volume":"82","author":"J Tian","year":"2023","unstructured":"Tian J, Zhang D, Yao X, Huang Y, Lu Q. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis. 2023;82(3):351\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"549_CR23","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/psp4.12224","volume":"6","author":"JT Ryman","year":"2017","unstructured":"Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacomet Syst Pharmacol. 2017;6(9):576\u201388.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"549_CR24","doi-asserted-by":"crossref","unstructured":"Brunner HI, Ant\u00f3n J, Calvo-Penad\u00e9s I, et al. Pharmacokinetics, pharmacodynamics, and safety of subcutaneous belimumab in pediatric patients with systemic lupus erythematosus: a multicenter, open-label trial. Arthritis Care Res. 2026;78(6):761-770.","DOI":"10.1002\/acr.25700"},{"issue":"2","key":"549_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40272-020-00382-7","volume":"22","author":"ZH Temrikar","year":"2020","unstructured":"Temrikar ZH, Suryawanshi S, Meibohm B. Pharmacokinetics and clinical pharmacology of monoclonal antibodies in pediatric patients. Paediatr Drugs. 2020;22(2):199\u2013216.","journal-title":"Paediatr Drugs"},{"issue":"3","key":"549_CR26","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1084\/jem.20021829","volume":"197","author":"C Chaudhury","year":"2003","unstructured":"Chaudhury C, Mehnaz S, Robinson JM, et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med. 2003;197(3):315\u201322.","journal-title":"J Exp Med"},{"key":"549_CR27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.5639\/gabij.2023.1202.010","volume":"12","author":"SN Athalye","year":"2023","unstructured":"Athalye SN, Baruah DB, Mittra S, et al. Ethic sensitivity assessments in biosimiar monoclonal antibodies clinical development programmes: necessary or not? GaBI J. 2023;12:61\u20136.","journal-title":"GaBI J."},{"issue":"5","key":"549_CR28","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/jcph.231","volume":"54","author":"K Chiba","year":"2014","unstructured":"Chiba K, Yoshitsugu H, Kyosaka Y, et al. A comprehensive review of the pharmacokinetics of approved therapeutic monoclonal antibodies in Japan: are Japanese phase I studies still needed? J Clin Pharmacol. 2014;54(5):483\u201394.","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"549_CR29","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/jcph.70065","volume":"65","author":"K Fukuhara","year":"2025","unstructured":"Fukuhara K, Tanetsugu Y, Wada S, Muto C, Kawai N. Evaluation of characteristics and ethnic sensitivity for FDA-approved drugs with racial and ethnic differences in pharmacokinetics, safety, and efficacy. J Clin Pharmacol. 2025;65(11):1381\u201391.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"549_CR30","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/jcph.1978","volume":"62","author":"A Ramamoorthy","year":"2022","unstructured":"Ramamoorthy A, Kim HH, Shah-Williams E, Zhang L. Racial and ethnic differences in drug disposition and response: review of new molecular entities approved between 2014 and 2019. J Clin Pharmacol. 2022;62(4):486\u201393.","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"549_CR31","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1177\/0091270011411192","volume":"52","author":"H Zhou","year":"2012","unstructured":"Zhou H, Tsukamoto Y, Davis HM. Should clinical pharmacokinetic bridging studies between Caucasian and Asian populations be required for approval of monoclonal antibodies? J Clin Pharmacol. 2012;52(8):1273\u20136.","journal-title":"J Clin Pharmacol"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-026-00549-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-026-00549-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-026-00549-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:01:49Z","timestamp":1792785709000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-026-00549-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":31,"alternative-id":["549"],"URL":"https:\/\/doi.org\/10.1007\/s40268-026-00549-6","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Junyi Wu, Richard Dimelow, Scott Marshall, are employees of GSK and hold financial equities in GSK. Xuan Zhou was an employee of GSK at the time of the analysis.","order":1,"name":"Ethics","label":"Conflicts of Interest\/Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study followed International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice. Prior to commencing study-specific procedures, approval of national\/regional\/investigational sites, ethics committees, or institutional review boards was obtained;","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was provided from each patient\u2019s parent(s)\/legal guardian(s), and from patients turning age 18 years to continue participation. Included studies were approved by the relevant institutional review boards or ethics committees and conducted in accordance with the Declaration of Helsinki 2008 and its later amendments, Council for International Organization of Medical Sciences International Ethical Guidelines, applicable International Organization for Standardization 14155 medical device guidelines, the European Medical Device Regulation 2017\/745 for clinical device research, and other applicable laws and regulations. Patients and their legal representatives were informed that study participation was voluntary. Prior to study enrollment, investigative sites obtained signed informed consent from patients that met the requirements of 21 Code of Federal Regulations 50, local regulations, ICH guidelines, and Health Insurance Portability and Accountability Act requirements, where applicable, and the institutional review board\/independent ethics committee or study center.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No direct subject contact or primary collection of individual human subject data occurred in this study, and study results are in tabular form and aggregate analyses that omit subject identification, therefore informed consent for study participation and study publication was not required.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Please refer to the GSK weblink to access GSK\u2019s data-sharing policies and as applicable seek anonymized subject-level data via the link\n                      \n                      .","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The modeling code can be provided on request.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed to the conception or design of the study. JW contributed to the acquisition and analysis of data. All authors contributed to the interpretation of the data. All authors reviewed and approved the final version.","order":7,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}